Monday - April 6, 2026
Tipoffs for Bangor, Maine (New England) Newsletter for Thursday February 19, 2026 ( 7 items )  

BloombergNEF: Study Shows Sustainable Energy Technologies Met Rising Demand Growth in 2025 Despite Uncertainty
LONDON, England, Feb. 19 (TNSrep) -- BloombergNEF, a part of Bloomberg, issued the following news release: * * * New Study Shows Sustainable Energy Technologies Met Rising Demand Growth in 2025 Despite Uncertainty KEY TAKEAWAYS * Fourteenth Sustainable Energy in America Factbook highlights national data on the U.S. energy expansion in 2025 * In 2025, U.S. electricity demand rose considerably for the first time in decades, coinciding with rising electricity prices. At the same time, far-rea  more

Clinical trial findings question value of brain filters in heart valve surgery
GALVESTON, Texas, Feb. 18 -- The University of Texas Medical Branch issued the following news release: * * * Clinical trial findings question value of brain filters in heart valve surgery * An editorial authored by Dr. Hani Jneid, director of the Sealy Heart and Vascular Institute at UTMB, examines findings from a large clinical trial that found special "brain-protection" devices used during a common heart valve procedure did not reduce the risk of stroke or death for most patients. The pr  more

Larson, Bysiewicz, Zoppo-Sassu Announce $3.15 Million in Federal Funding to Construct First Active Shooter Training Facility for First Responders in New England
WASHINGTON, Feb. 18 -- Rep. John B. Larson, D-Connecticut, issued the following news release: * * * Larson, Bysiewicz, Zoppo-Sassu Announce $3.15 Million in Federal Funding to Construct First Active Shooter Training Facility for First Responders in New England * Bristol, CT - Last night, Rep. John B. Larson (CT-01) announced $3.15 million in new federal funding for the Bristol Fire and Police Department, to construct the first active shooter training facility for first responders in New Engl  more

Massachusetts Receives Final Approval to Enable Universal Broadband Coverage
BOSTON, Massachusetts, Feb. 18 -- Gov. Maura Healey, D-Massachusetts, issued the following news release: * * * Massachusetts Receives Final Approval to Enable Universal Broadband Coverage * BOSTON -The Healey-Driscoll Administration received approval for $18.8 million under the National Telecommunications and Information Administration's (NTIA) Broadband Equity, Access, and Deployment (BEAD) program. The funding will enable the Massachusetts Technology Collaborative's (MassTech) Massachusett  more

Plymouth Woman Pleads Guilty to PPP Fraud and Money Laundering
BOSTON, Massachusetts, Feb. 18 -- The office of the U.S. Attorney for the District of Massachusetts posted the following news release: * * * Plymouth Woman Pleads Guilty to PPP Fraud and Money Laundering * BOSTON - A Plymouth woman has pleaded guilty in federal court in Boston to money laundering and submitting fraudulent Paycheck Protection Program (PPP) loan applications on behalf of herself and her father. Katherine Reynolds, 66, pleaded guilty on Feb. 12, 2026 to two counts of wire fra  more

Rybrevant Faspro Receives U.S. FDA Breakthrough Therapy Designation for Patients With Advanced Head and Neck Cancer
RARITAN, New Jersey, Feb. 19 -- Johnson and Johnson Innovative Medicine issued the following news release on Feb. 18, 2026: * * * RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO(TM) beyond lung cancer * Johnson & Johnson (NYSE:JNJ  more

ViiV Healthcare's Long-Acting Cabenuva for HIV Demonstrates Superior Efficacy Compared to Daily Oral Therapy for People With Adherence Challenges; Results Published in NEJM
LONDON, England, Feb. 19 (TNSjou) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release: * * * ViiV Healthcare's long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM - Final data from LATITUDE study show switch to long-acting injectable treatment reduced the risk of virological failure by nearly half for study participan  more